HRP20231280T1 - Anti-her2 biparatopski antitijelo-konjugati lijeka i načini uporabe - Google Patents
Anti-her2 biparatopski antitijelo-konjugati lijeka i načini uporabe Download PDFInfo
- Publication number
- HRP20231280T1 HRP20231280T1 HRP20231280TT HRP20231280T HRP20231280T1 HR P20231280 T1 HRP20231280 T1 HR P20231280T1 HR P20231280T T HRP20231280T T HR P20231280TT HR P20231280 T HRP20231280 T HR P20231280T HR P20231280 T1 HRP20231280 T1 HR P20231280T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- her2
- drug conjugate
- antigen
- conjugate according
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title claims 25
- 229940049595 antibody-drug conjugate Drugs 0.000 title claims 25
- 229920001184 polypeptide Polymers 0.000 claims 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims 34
- 239000000427 antigen Substances 0.000 claims 18
- 102000036639 antigens Human genes 0.000 claims 18
- 108091007433 antigens Proteins 0.000 claims 18
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 14
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 14
- 150000001413 amino acids Chemical class 0.000 claims 13
- 238000012986 modification Methods 0.000 claims 12
- 230000004048 modification Effects 0.000 claims 12
- 108010044540 auristatin Proteins 0.000 claims 6
- 239000000562 conjugate Substances 0.000 claims 5
- 101100330727 Arabidopsis thaliana DAR6 gene Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 229960002087 pertuzumab Drugs 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (24)
1. Konjugat protutijela i lijeka koji sadrži anti-HER2 biparatopsko protutijelo konjugirano s analogom auristatina preko poveznice (L) pri niskom prosječnom omjeru lijeka prema protutijelu (DAR),
pri čemu anti-HER2 biparatopsko protutijelo sadrži prvi polipeptidni konstrukt koji se veže na antigen, koji veže prvi epitop HER2 i drugi konstrukt polipeptida, koji se veže na antigen, koji se veže na drugi epitop HER2, pri čemu su prvi i drugi epitop HER2 na različitim domenama HER2,
pri čemu analog auristatina i povezivač imaju opću formulu (X):
[image]
pri čemu:
R1 je odabran između:
[image]
L je povezivač, i
[image]
predstavlja točku pričvršćivanja poveznice na anti-HER2 biparatopsko protutijelo, i
pri čemu je niski prosječni DAR prosječni DAR između 1,5 i 2,5.
2. Konjugat antitijelo-lijek prema zahtjevu 1, pri čemu R1 je:
[image]
3. Konjugat antitijelo-lijek prema zahtjevu 1 ili 2, naznačen time, da je prosječni DAR između 1,8 i 2,5.
4. Konjugat antitijelo-lijek prema zahtjevu 1 ili 2, naznačen time, da je prosječni DAR oko 2,0.
5. Konjugat antitijelo-lijek prema bilo kojem od zahtjeva 1 do 4, naznačen time, da konjugat sadrži između oko 10% i oko 30% DAR0 vrsta.
6. Konjugat antitijelo-lijek prema bilo kojem od zahtjeva 1 do 4, naznačen time, da konjugat sadrži između oko 10% i oko 25% DAR0 vrsta.
7. Konjugat antitijelo-lijek prema bilo kojem od zahtjeva 1 do 4, pri čemu, konjugat sadrži između oko 15% i oko 25% DAR0 vrsta.
8. Konjugat protutijelo-lijek prema bilo kojem od zahtjeva 1 do 7, pri čemu, konjugat sadrži između 0% i oko 15% DAR6 ili više vrsta, ili između oko 0% i oko 10% DAR6 ili više vrsta.
9. Konjugat protutijelo-lijek prema bilo kojem od Zahtjeva 1 do 8, pri čemu, je L linker koji se može cijepati, izborno linker koji se može cijepati proteazom.
10. Konjugat protutijelo-lijek prema bilo kojem od zahtjeva 1 do 9, pri čemu, L ima opću formulu(VI):
[image]
gdje:
Z je funkcionalna skupina sposobna reagirati s ciljnom skupinom na anti-HER2 biparatopnom protutijelu;
Str je nosilo;
AA1i AA2su svaki neovisno aminokiselina, pri čemu AA1-[AA2]mtvori mjesto cijepanja proteazom;
X je samospaljiva skupina;
D je točka dodira za analog auristatina;
s je 0 ili 1;
m je cijeli broj između 1 i 4, i
o je 0, 1 ili 2,
izborno gdje je s 1 i o je 0.
11. Konjugat antitijelo-lijek prema bilo kojem od zahtjeva 1 do 9, pri čemu, L ima opću formulu(VI):
[image]
gdje:
AS- je točka pričvršćivanja za anti-HER2 biparatopsko protutijelo;
Y je jedna ili više dodatnih komponenata povezivača, ili je odsutan, i
D je točka pričvršćivanja za analog auristatina;
12. Konjugat antitijelo-lijek prema bilo kojem od Zahtjeva 1 do 8, naznačen time, da analog auristatina i linker imaju strukturu:
[image]
gdje je AS- točka vezanja na anti-HER2 biparatopsko protutijelo.
13. Konjugat antitijelo-lijek u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačen time, da se anti-HER2 biparatopsko antitijelo veže na HER2 s višim afinitetom u usporedbi s odgovarajućim bivalentnim monospecifičnim antitijelom, i/ili pri čemu anti-HER2 biparatopno antitijelo pokazuje veća internalizacija u stanice koje eksprimiraju HER2 u usporedbi s odgovarajućim dvovalentnim monospecifičnim antitijelom.
14. Konjugat antitijelo-lijek prema bilo kojem od Zahtjeva 1 do 13, naznačen time, da je prvi polipeptidni konstrukt koji se veže na antigen scFv, a drugi polipeptidni konstrukt koji se veže na antigen je Fab.
15. Konjugat antitijelo-lijek prema bilo kojem od Zahtjeva 1 do 14, naznačen time, da je prvi HER2 epitop na ECD4 od HER2, a drugi HER2 epitop je na ECD2 od HER2, izborno gdje se prvi polipeptidni konstrukt koji veže antigen natječe s trastuzumabom. za vezanje na HER2, i/ili gdje se drugi polipeptidni konstrukt koji veže antigen natječe s pertuzumabom za vezanje na HER2.
16. Konjugat antitijela i lijeka prema bilo kojem od zahtjeva 1 do 15, naznačen time što:
(a) prvi polipeptidni konstrukt koji se veže na antigen sadrži CDR sekvence iz kraka za vezanje ECD4 bilo kojeg od v5019, v5020, v7091, v10000, v6902, v6903 ili v6717, a drugi polipeptidni konstrukt koji se veže na antigen sadrži CDR sekvence iz ECD2-veznog kraka bilo kojeg od v5019, v5020, v7091, v10000, v6902, v6903, v6717, v7133, v15079, v15080, v15081, v15082, v15083, v15084 ili v15085, ili
(b) prvi polipeptidni konstrukt koji se veže na antigen sadrži CDR sekvence iz ECD4-vezujućeg kraka v10000, a drugi polipeptidni konstrukt koji se veže na antigen sadrži CDR sekvence iz ECD2-vezujućeg kraka v10000.
17. Konjugat antitijelo-lijek prema bilo kojem od Zahtjeva 1 do 15, naznačen time, da prvi polipeptidni konstrukt koji veže antigen sadrži CDR sekvence navedene u SEQ ID NO: 67, 68, 69, 70, 71 i 72, i drugi polipeptidni konstrukt koji veže antigen sadrži CDR sekvence navedene u SEQ ID NO: 27, 28, 29, 39, 40 i 41.
18. Konjugat antitijelo-lijek u skladu s bilo kojim od patentnih zahtjeva 1 do 15, naznačen time, da prvi polipeptidni konstrukt koji se veže na antigen sadrži VH sekvencu kako je navedeno u SEQ ID NO: 66 i VL sekvencu kako je navedeno u SEQ ID NO: 65, a drugi polipeptidni konstrukt koji veže antigen sadrži VH sekvencu kako je prikazano u SEQ ID NO: 38 i VL slijed kako je navedeno u SEQ ID NO: 26.
19. Konjugat protutijelo-lijek prema bilo kojem od Zahtjeva 1 do 18, naznačen time, da anti-HER2 biparatopsko protutijelo dalje sadrži skelu koja je IgGFc regija, pri čemu su prvi i drugi polipeptidni konstrukti koji vežu antigen operativno povezani na skelu, i pri čemu je IgG Fc regija heterodimerna Fc regija koja sadrži modificiranu CH3 domenu.
20. Konjugat antitijelo-lijek prema zahtjevu 19, naznačen time što modificirana CH3 domena sadrži prvu polipeptidnu sekvencu i drugu polipeptidnu sekvencu, i gdje:
(a) prva polipeptidna sekvenca modificirane CH3 domene sadrži aminokiselinske modifikacije L351Y, F405A i Y407V, a druga polipeptidna sekvenca modificirane CH3 domene sadrži aminokiselinske modifikacije T366L, K392M i T394W; ili
(b) prva polipeptidna sekvenca modificirane CH3 domene sadrži aminokiselinske modifikacije L351Y, F405A i Y407V, a druga polipeptidna sekvenca modificirane CH3 domene sadrži aminokiselinske modifikacije T366L, K392L i T394W; ili
(c) prva polipeptidna sekvenca modificirane CH3 domene sadrži aminokiselinske modifikacije T350V, L351Y, F405A i Y407V, a druga polipeptidna sekvenca modificirane CH3 domene sadrži aminokiselinske modifikacije T350V, T366L, K392M i T394W; ili
(d) prva polipeptidna sekvenca modificirane CH3 domene sadrži aminokiselinske modifikacije T350V, L351Y, F405A i Y407V, a druga polipeptidna sekvenca modificirane CH3 domene sadrži aminokiselinske modifikacije T350V, T366L, K392L i T394W; ili
(e) prva polipeptidna sekvenca modificirane CH3 domene sadrži aminokiselinske modifikacije T350V, L351Y, S400E, F405A i Y407V, a druga polipeptidna sekvenca modificirane CH3 domene sadrži aminokiselinske modifikacije T350V, T366L, N390R, K392M i T394W.
21. Konjugat antitijelo-lijek prema zahtjevu 1, pri čemu R1 je :
(a) prvi polipeptidni konstrukt anti-HER2 biparatopnog antitijela koji se veže na antigen je scFv koji sadrži VH sekvencu kako je navedeno u SEQ ID NO: 66 i VL sekvencu kako je navedeno u SEQ ID NO: 65, i drugi antigen-vezujući polipeptidni konstrukt anti-HER2 biparatopnog protutijela je Fab koji sadrži VH sekvencu kako je prikazano u SEQ ID NO: 38 i VL sekvencu kako je navedeno u SEQ ID NO: 26;
(b) anti-HER2 biparatopsko protutijelo nadalje sadrži skelu koja je heterodimerna IgG Fc regija koja sadrži modificiranu CH3 domenu, pri čemu su prvi i drugi polipeptidni konstrukt koji veže antigen operativno povezani na skelu, pri čemu modificirana CH3 domena sadrži prvi polipeptidni slijed i drugi polipeptidni slijed, prvi polipeptidni slijed koji sadrži aminokiselinske modifikacije T350V, L351Y, F405A i Y407V, i drugi polipeptidni slijed koji sadrži aminokiselinske modifikacije T350V, T366L, K392L i T394W;
(c) analog auristatina i poveznica imaju strukturu:
[image]
gdje je AS- točka vezanja za anti-HER2 biparatopsko protutijelo;
(d) prosječni DAR je između 1,8 i 2,5, i
(e) konjugat sadrži između oko 10% i oko 25% DAR0 vrsta.
22. Farmaceutski pripravak, naznačen time, da sadrži konjugat antitijelo-lijek prema bilo kojem od zahtjeva 1 do 21 i farmaceutski prihvatljiv nosač ili razrjeđivač.
23. Konjugat antitijelo-lijek prema bilo kojem od Zahtjeva 1 do 21, naznačen time, da se koristi za liječenje raka koji eksprimira HER2 kod subjekta kojem je to potrebno.
24. Konjugat antitijelo-lijek za upotrebu prema Zahtjevu 23, naznačen time što je rak koji eksprimira HER2 rak dojke, rak jajnika, rak pluća ili rak želuca.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862642483P | 2018-03-13 | 2018-03-13 | |
US201862658477P | 2018-04-16 | 2018-04-16 | |
US201862743884P | 2018-10-10 | 2018-10-10 | |
PCT/CA2019/050303 WO2019173911A1 (en) | 2018-03-13 | 2019-03-12 | Anti-her2 biparatopic antibody-drug conjugates and methods of use |
EP19766478.2A EP3765525B1 (en) | 2018-03-13 | 2019-03-12 | Anti-her2 biparatopic antibody-drug conjugates and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20231280T1 true HRP20231280T1 (hr) | 2024-02-02 |
Family
ID=67908692
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20231280TT HRP20231280T1 (hr) | 2018-03-13 | 2019-03-12 | Anti-her2 biparatopski antitijelo-konjugati lijeka i načini uporabe |
Country Status (21)
Country | Link |
---|---|
US (3) | US20210260210A1 (hr) |
EP (2) | EP3765525B1 (hr) |
JP (1) | JP2021515793A (hr) |
KR (1) | KR20200131840A (hr) |
CN (1) | CN112020519A (hr) |
AU (1) | AU2019235634A1 (hr) |
BR (1) | BR112020018618A2 (hr) |
CA (1) | CA3093477A1 (hr) |
DK (1) | DK3765525T3 (hr) |
ES (1) | ES2958933T3 (hr) |
FI (1) | FI3765525T3 (hr) |
HR (1) | HRP20231280T1 (hr) |
HU (1) | HUE063489T2 (hr) |
IL (1) | IL277049B2 (hr) |
MX (1) | MX2020009469A (hr) |
PL (1) | PL3765525T3 (hr) |
PT (1) | PT3765525T (hr) |
RS (1) | RS64690B1 (hr) |
SG (1) | SG11202008770QA (hr) |
TW (1) | TWI822740B (hr) |
WO (1) | WO2019173911A1 (hr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170355779A1 (en) * | 2014-11-27 | 2017-12-14 | Zymeworks Inc. | Methods of using bispecific antigen-binding constructs targeting her2 |
WO2022228422A1 (zh) * | 2021-04-26 | 2022-11-03 | 轩竹生物科技股份有限公司 | 一种双特异抗体偶联物 |
WO2023141714A1 (en) * | 2022-01-26 | 2023-08-03 | Zymeworks Bc Inc. | Methods of using anti-her2 biparatopic antibody-drug conjugates in the treatment of cancer |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US20040010134A1 (en) | 2000-04-12 | 2004-01-15 | Rosen Craig A. | Albumin fusion proteins |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
US7256257B2 (en) | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
ES2556641T3 (es) | 2002-07-31 | 2016-01-19 | Seattle Genetics, Inc. | Conjugados de fármacos y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa |
US8399618B2 (en) | 2004-10-21 | 2013-03-19 | Xencor, Inc. | Immunoglobulin insertions, deletions, and substitutions |
SG195524A1 (en) | 2003-11-06 | 2013-12-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
WO2005082023A2 (en) | 2004-02-23 | 2005-09-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
AU2005286607B2 (en) | 2004-09-23 | 2011-01-27 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
WO2006105338A2 (en) | 2005-03-31 | 2006-10-05 | Xencor, Inc. | Fc VARIANTS WITH OPTIMIZED PROPERTIES |
GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
CN101682184A (zh) * | 2006-11-24 | 2010-03-24 | 杰米那资产管理(6)有限公司 | 供电监控系统 |
US8455622B2 (en) | 2006-12-01 | 2013-06-04 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
PT2506871T (pt) | 2009-11-30 | 2016-11-07 | Janssen Biotech Inc | Mutantes de fc de anticorpos com funções efetoras inutilizadas |
EP2516462B1 (en) | 2009-12-23 | 2015-05-06 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them |
JP6039428B2 (ja) * | 2010-03-04 | 2016-12-07 | シムフォゲン・アクティーゼルスカブSymphogen A/S | 抗her2抗体および組成物 |
WO2011135040A1 (en) | 2010-04-30 | 2011-11-03 | F. Hoffmann-La Roche Ag | Fluorescent antibody fusion protein, its production and use |
CN114246952A (zh) | 2010-06-08 | 2022-03-29 | 基因泰克公司 | 半胱氨酸改造的抗体和偶联物 |
JP6167040B2 (ja) | 2010-11-05 | 2017-07-19 | ザイムワークス,インコーポレイテッド | Fcドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計 |
AU2012222833B2 (en) | 2011-03-03 | 2017-03-16 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
SG193554A1 (en) | 2011-03-29 | 2013-11-29 | Roche Glycart Ag | Antibody fc variants |
US20140170148A1 (en) | 2011-04-20 | 2014-06-19 | Genmab A/S | Bispecific antibodies against her2 |
WO2012148584A1 (en) * | 2011-04-29 | 2012-11-01 | Becton Dickinson & Co. | Cell sorter system and method |
PL2773671T3 (pl) * | 2011-11-04 | 2022-01-24 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc |
AU2013279099A1 (en) * | 2012-06-19 | 2014-12-18 | Polytherics Limited | Novel process for preparation of antibody conjugates and novel antibody conjugates |
IN2015DN01115A (hr) | 2012-07-13 | 2015-06-26 | Zymeworks Inc | |
JP2015532306A (ja) | 2012-10-15 | 2015-11-09 | チューリッヒ大学 | 癌治療のための二重特異性her2リガンド |
CN109180815B (zh) | 2012-11-20 | 2022-06-21 | 赛诺菲 | 抗ceacam5抗体及其用途 |
AU2014240012A1 (en) | 2013-03-15 | 2015-09-24 | Abbvie Inc. | Antibody drug conjugate (ADC) purification |
EP2777714A1 (en) | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
WO2014182970A1 (en) * | 2013-05-08 | 2014-11-13 | Zymeworks Inc. | Bispecific her2 and her3 antigen binding constructs |
RU2655439C2 (ru) | 2013-05-31 | 2018-05-28 | Займворкс Инк. | Гетеромультимеры с уменьшенной или подавленной эффекторной функцией |
US9877080B2 (en) * | 2013-09-27 | 2018-01-23 | Samsung Electronics Co., Ltd. | Display apparatus and method for controlling thereof |
MX2016006572A (es) | 2013-11-27 | 2016-12-09 | Zymeworks Inc | Construcciones de union a antigenos biespecificas dirigidas a her2. |
JP6510532B2 (ja) | 2013-12-20 | 2019-05-08 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性her2抗体及び使用方法 |
EP3086815B1 (en) * | 2013-12-27 | 2022-02-09 | Zymeworks Inc. | Sulfonamide-containing linkage systems for drug conjugates |
KR20160099725A (ko) | 2014-01-10 | 2016-08-22 | 신톤 바이오파머슈티칼즈 비.브이. | 자궁내막암의 치료에서 사용하기 위한 듀오카르마이신 adc |
TWI701042B (zh) * | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
CA2943299A1 (en) | 2014-04-11 | 2015-10-15 | Medimmune, Llc | Bispecific her2 antibodies |
JP6517240B2 (ja) | 2014-05-22 | 2019-05-22 | シントン・バイオファーマシューティカルズ・ビー.ブイ.Synthon Biopharmaceuticals B.V. | 抗体へのリンカー薬物の部位特異的コンジュゲーションおよび得られるadc |
RS62860B1 (sr) * | 2014-09-17 | 2022-02-28 | Zymeworks Inc | Citotoksična i antimitotička jedinjenja, i postupci upotrebe istih |
US20170355779A1 (en) | 2014-11-27 | 2017-12-14 | Zymeworks Inc. | Methods of using bispecific antigen-binding constructs targeting her2 |
EP3294772A4 (en) * | 2015-05-13 | 2019-05-01 | Zymeworks Inc. | BINDING CONSTRUCTS TO HER2 TARGETING ANTIGEN |
EP3383909B1 (en) | 2015-11-30 | 2020-06-17 | AbbVie Inc. | Anti-human lrrc15 antibody drug conjugates and methods for their use |
WO2017185177A1 (en) | 2016-04-25 | 2017-11-02 | Zymeworks Inc. | Methods of using bispecific antigen-binding constructs targeting her2 |
RS60663B1 (sr) | 2016-05-17 | 2020-09-30 | Abbvie Biotherapeutics Inc | Konjugati anti-cmet antitelo-lek i metodi za njihovu primenu |
US10377833B2 (en) | 2016-07-22 | 2019-08-13 | Beijing Mabworks Biotech Co., Ltd. | Bispecific anti-HER2 antibody |
CN107446045A (zh) * | 2016-07-22 | 2017-12-08 | 北京天广实生物技术股份有限公司 | 一种抗her2的抗体、其药物组合物及用途 |
-
2019
- 2019-03-12 HU HUE19766478A patent/HUE063489T2/hu unknown
- 2019-03-12 IL IL277049A patent/IL277049B2/en unknown
- 2019-03-12 ES ES19766478T patent/ES2958933T3/es active Active
- 2019-03-12 CN CN201980027418.2A patent/CN112020519A/zh active Pending
- 2019-03-12 SG SG11202008770QA patent/SG11202008770QA/en unknown
- 2019-03-12 US US16/980,318 patent/US20210260210A1/en not_active Abandoned
- 2019-03-12 PL PL19766478.2T patent/PL3765525T3/pl unknown
- 2019-03-12 MX MX2020009469A patent/MX2020009469A/es unknown
- 2019-03-12 AU AU2019235634A patent/AU2019235634A1/en active Pending
- 2019-03-12 RS RS20230943A patent/RS64690B1/sr unknown
- 2019-03-12 DK DK19766478.2T patent/DK3765525T3/da active
- 2019-03-12 EP EP19766478.2A patent/EP3765525B1/en active Active
- 2019-03-12 HR HRP20231280TT patent/HRP20231280T1/hr unknown
- 2019-03-12 JP JP2020548783A patent/JP2021515793A/ja active Pending
- 2019-03-12 WO PCT/CA2019/050303 patent/WO2019173911A1/en active Application Filing
- 2019-03-12 KR KR1020207028457A patent/KR20200131840A/ko unknown
- 2019-03-12 CA CA3093477A patent/CA3093477A1/en active Pending
- 2019-03-12 PT PT197664782T patent/PT3765525T/pt unknown
- 2019-03-12 FI FIEP19766478.2T patent/FI3765525T3/fi active
- 2019-03-12 EP EP23176808.6A patent/EP4253421A3/en active Pending
- 2019-03-12 BR BR112020018618-0A patent/BR112020018618A2/pt unknown
- 2019-03-13 TW TW108108455A patent/TWI822740B/zh active
- 2019-10-07 US US16/594,728 patent/US11000598B2/en active Active
-
2021
- 2021-03-23 US US17/210,081 patent/US20210346508A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
HUE063489T2 (hu) | 2024-01-28 |
DK3765525T3 (da) | 2023-10-16 |
US11000598B2 (en) | 2021-05-11 |
EP4253421A2 (en) | 2023-10-04 |
RU2020132555A (ru) | 2022-04-13 |
WO2019173911A1 (en) | 2019-09-19 |
IL277049B1 (en) | 2023-10-01 |
AU2019235634A1 (en) | 2020-10-22 |
EP4253421A3 (en) | 2024-01-03 |
KR20200131840A (ko) | 2020-11-24 |
JP2021515793A (ja) | 2021-06-24 |
EP3765525A1 (en) | 2021-01-20 |
RS64690B1 (sr) | 2023-11-30 |
MX2020009469A (es) | 2021-01-29 |
TW202003585A (zh) | 2020-01-16 |
FI3765525T3 (fi) | 2023-10-16 |
TWI822740B (zh) | 2023-11-21 |
IL277049B2 (en) | 2024-02-01 |
US20210346508A1 (en) | 2021-11-11 |
IL277049A (en) | 2020-10-29 |
EP3765525B1 (en) | 2023-07-19 |
SG11202008770QA (en) | 2020-10-29 |
BR112020018618A2 (pt) | 2020-12-29 |
US20210260210A1 (en) | 2021-08-26 |
US20200108152A1 (en) | 2020-04-09 |
ES2958933T3 (es) | 2024-02-16 |
CA3093477A1 (en) | 2019-09-19 |
PL3765525T3 (pl) | 2023-12-27 |
EP3765525A4 (en) | 2022-03-02 |
CN112020519A (zh) | 2020-12-01 |
PT3765525T (pt) | 2023-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11566071B2 (en) | Nucleic acid molecules encoding anti-GPRC5D antibodies | |
ES2943577T3 (es) | Direccionamiento doble | |
JP2018520092A5 (hr) | ||
JP2020508655A5 (hr) | ||
HRP20231280T1 (hr) | Anti-her2 biparatopski antitijelo-konjugati lijeka i načini uporabe | |
KR20160024923A (ko) | 신규한 항체 기본구조 | |
RU2013142600A (ru) | Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы | |
US20230312722A1 (en) | Anti-b7h4 antibody, and bispecific antibody and use thereof | |
US11623963B2 (en) | Cysteine engineered antigen-binding molecules | |
IL305954A (en) | Nectin-4 protein antibody and extacan compounds | |
CN113121639B (zh) | 澳瑞他汀类似物及其偶联物、其制备方法及其应用 | |
CN116940598A (zh) | 用于治疗表达cldn18.2的实体瘤的cldn18.2/cd3双特异性抗体 | |
NZ732567B2 (en) | Antibodies targeting g-protein coupled receptor and methods of use | |
JPWO2019173911A5 (hr) | ||
KR20130097628A (ko) | 아포리포단백질을 포함하는 항체-약물 결합체 | |
NZ807450A (en) | Antibodies binding to gprc5d | |
JPWO2019165326A5 (hr) | ||
RU2010148418A (ru) | Иммуноглобулины с двойным вариабельным доменом и их применение | |
JPWO2019191563A5 (hr) |